Concepedia

Patricia Keegan

PK

98

Publications

12.2K

Citations

56

H-Index

1955

Active since

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Emory University

BioReliance (United States)

National Institutes of Health

Patricia Keegan is an author at United States Food and Drug Administration specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

1955–2024

98

Publications

98

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Leigh Marcus, Steven J. Lemery, Patricia Keegan et al. · Clinical Cancer Research · 2019 · 1.1K citations

, , +13

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

Steven J. Lemery, Patricia Keegan, Richard Pazdur · New England Journal of Medicine · 2017 · 643 citations

, , +20

FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

Martin H. Cohen, Yuan Li Shen, Patricia Keegan et al. · The Oncologist · 2009 · 635 citations · Full text

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zixian Wang, Chengxu Cui, Jun Yao et al. · Cancer Cell · 2022 · 523 citations · Full text

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal et al. · The Oncologist · 2016 · 473 citations · Full text

Rows per page

1–5 of 98